Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aclarubicin: experimental and clinical experience.

H J Röthig, H P Kraemer, H H Sedlacek

    Drugs Under Experimental and Clinical Research
    |January 1, 1985
    PubMed
    Summary

    Aclarubicin, an anthracycline antibiotic, demonstrates significant efficacy in treating acute leukemia and solid tumors with reduced cardiotoxicity compared to other anthracyclines. Its therapeutic index is favorable, especially with optimized dosing schedules.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A Novel Magnetic Field Device for Inducing Hyperthermia Using Magnetic Nanoparticles.

    Biomedizinische Technik. Biomedical engineering·2013
    Same author

    Mechanisms of action of flavopiridol.

    Critical reviews in oncology/hematology·2001
    Same author

    Pharmacological aspects of targeting cancer gene therapy to endothelial cells.

    Critical reviews in oncology/hematology·2001
    Same author

    Kinase inhibitors in cancer therapy: a look ahead.

    Drugs·2000
    Same author

    Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy.

    Gene therapy·2000
    Same author

    Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells.

    International journal of cancer·1999

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Therapeutics

    Background:

    • Aclarubicin is a cytostatic anthracycline antibiotic discovered in 1975.
    • It exhibits lower cardiotoxicity and is non-mutagenic compared to other anthracyclines.
    • Aclarubicin can stimulate tumor cell differentiation.

    Purpose of the Study:

    • To evaluate the efficacy and toxicity of aclarubicin in clinical trials.
    • To determine optimal dosing schedules for aclarubicin in various cancers.
    • To compare aclarubicin's therapeutic index with doxorubicin and daunorubicin.

    Main Methods:

    • Clinical trials were conducted using two dose schedules: 25 mg/m2/day (days 1-7) for acute leukemia and 30 mg/m2/day (days 1-4) for solid tumors.
    • Efficacy was assessed by remission rates in acute myeloid leukemia (AML) and response in breast and thyroid cancers.
    • Toxicity profiles, including cardiotoxicity, mutagenicity, and side effects, were monitored.

    Main Results:

    • Aclarubicin achieved 58% complete remissions in first relapse of AML.
    • Efficacy in breast and thyroid cancers was comparable to doxorubicin.
    • Markedly reduced side effects were observed, with no alopecia or congestive heart failure, though myelosuppression was common.

    Conclusions:

    • Aclarubicin offers a favorable therapeutic index, particularly with appropriate dosing.
    • It is a promising chemotherapeutic agent for acute leukemia and solid tumors, with an improved safety profile.
    • Further clinical investigation is warranted for aclarubicin in cancer treatment.

    Related Experiment Videos